Rapport Therapeutics, Inc. Common Stock (RAPP) Balance Sheet

The balance sheet has expanded significantly, primarily due to the 2024 IPO and subsequent capital raises, which have funded the ramp into pivotal trials. However, the trajectory is bifurcated: while equity and cash have grown, the accumulated deficit has deepened to -$311.7M, indicating that the company is consuming capital faster than it is generating returns. This suggests a reliance on external funding to sustain operations, with the balance sheet strength contingent on continued access to equity markets.

The company's debt is minimal and appears to be primarily lease-related, given the small PPE base. The low leverage is a positive signal for solvency, but it also underscores that the company is entirely equity-funded, which exposes it to dilution risk. As cash burn accelerates with pivotal trials, the absence of debt capacity suggests that future funding will likely come from equity issuance, potentially diluting existing shareholders.

The asset mix is dominated by cash and short-term investments, with negligible fixed assets and no goodwill or intangibles. This is typical of a clinical-stage biotech that outsources manufacturing and clinical operations. The lack of goodwill reduces impairment risk, but the minimal PPE also means there is little collateral for debt financing, reinforcing the reliance on equity. The asset base is highly liquid, which provides flexibility but also indicates that the company's value lies in its pipeline, not its physical assets.

The positive equity is a recent phenomenon, entirely attributable to capital raises rather than retained earnings. The accumulated deficit continues to grow, reflecting the pre-revenue status and heavy R&D spending. Stock-based compensation, which averaged around $7M per quarter, adds to dilution but is non-cash. The equity base is therefore 'fresh' but not internally generated, suggesting that the quality of equity is low in terms of organic value creation. Investors should monitor the pace of dilution as the company funds its pivotal trials.

The current ratio is exceptionally high, indicating strong short-term liquidity, but the absolute cash position is declining rapidly. With quarterly operating losses exceeding $60M, the current cash balance may only cover about one quarter of operations, based on the latest burn rate. This suggests that the company will need to raise additional capital in the near term, likely through equity issuance, to fund the ongoing pivotal trials. The high current ratio is somewhat misleading as it is driven by the cash balance, which is depleting quickly.